115 related articles for article (PubMed ID: 27771105)
1. [Which psychoactives substances are found in used syringes?].
Nordmann S; Nefau T; Micallef J; Duplessy C; Catusse JC; Frauger E
Therapie; 2023; 78(5S):S51-S57. PubMed ID: 27771105
[TBL] [Abstract][Full Text] [Related]
2. Substances detected in used syringes of injecting drug users across 7 cities in Europe in 2017 and 2018: The European Syringe Collection and Analysis Project Enterprise (ESCAPE).
Brunt TM; Lefrançois E; Gunnar T; Arponen A; Seyler T; Goudriaan AE; McAuley A; McKeown DA; Detrez V; Csorba J; Deimel D; Auwärter V; Kempf J; Karolak S; Nefau T
Int J Drug Policy; 2021 Sep; 95():103130. PubMed ID: 33487529
[TBL] [Abstract][Full Text] [Related]
3. [Nursing role and risk reduction for drug users].
Denize Y; Humbert S; Laborde A; Kreiss A; Waeckerlé G
Rev Infirm; 2018 Jan; 67(237):22-24. PubMed ID: 29331187
[TBL] [Abstract][Full Text] [Related]
4. Drug analysis of residual content of used syringes: a new approach for improving knowledge of injected drugs and drug user practices.
Néfau T; Charpentier E; Elyasmino N; Duplessy-Garson C; Levi Y; Karolak S
Int J Drug Policy; 2015 Apr; 26(4):412-9. PubMed ID: 25449054
[TBL] [Abstract][Full Text] [Related]
5. Drug residues in used syringes in Switzerland: A comparative study.
Lefrançois E; Augsburger M; Esseiva P
Drug Test Anal; 2018 May; 10(5):874-879. PubMed ID: 29111580
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus and HIV seroprevalences, sociodemographic characteristics, behaviors and access to syringes among drug users, a comparison of geographical areas in France, ANRS-Coquelicot 2011 survey.
Weill-Barillet L; Pillonel J; Semaille C; Léon L; Le Strat Y; Pascal X; Barin F; Jauffret-Roustide M
Rev Epidemiol Sante Publique; 2016 Sep; 64(4):301-12. PubMed ID: 26904917
[TBL] [Abstract][Full Text] [Related]
7. Analytical findings in used syringes from a syringe exchange program.
Fiorentin TR; Logan BK
Int J Drug Policy; 2020 Jul; 81():102770. PubMed ID: 32442881
[TBL] [Abstract][Full Text] [Related]
8. Substances injected at the Sydney supervised injecting facility: A chemical analysis of used injecting equipment and comparison with self-reported drug type.
Lefrancois E; Belackova V; Silins E; Latimer J; Jauncey M; Shimmon R; Mozaner Bordin D; Augsburger M; Esseiva P; Roux C; Morelato M
Drug Alcohol Depend; 2020 Apr; 209():107909. PubMed ID: 32145660
[TBL] [Abstract][Full Text] [Related]
9. Analysis of residual content of used syringes collected from low threshold facilities in Lausanne, Switzerland.
Lefrançois E; Esseiva P; Gervasoni JP; Lucia S; Zobel F; Augsburger M
Forensic Sci Int; 2016 Sep; 266():534-540. PubMed ID: 27514014
[TBL] [Abstract][Full Text] [Related]
10. [Surveillance system on drug abuse: Interest of the French national OPPIDUM program of French addictovigilance network].
Frauger E; Pochard L; Boucherie Q; Giocanti A; Chevallier C; Daveluy A; Gibaja V; Caous AS; Eiden C; Authier N; Le Boisselier R; Guerlais M; Jouanjus É; Lepelley M; Pizzoglio V; Pain S; Richard N; Micallef J;
Therapie; 2017 Sep; 72(4):491-501. PubMed ID: 28343650
[TBL] [Abstract][Full Text] [Related]
11. Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection.
Grebely J; Robaeys G; Bruggmann P; Aghemo A; Backmund M; Bruneau J; Byrne J; Dalgard O; Feld JJ; Hellard M; Hickman M; Kautz A; Litwin A; Lloyd AR; Mauss S; Prins M; Swan T; Schaefer M; Taylor LE; Dore GJ
Int J Drug Policy; 2023 Jan; 111():101669. PubMed ID: 26847504
[No Abstract] [Full Text] [Related]
12. Differences between users' and addiction medicine experts' harm and benefit assessments of licit and illicit psychoactive drugs: Input for psychoeducation and legalization/restriction debates.
Bonnet U; Specka M; Kanti AK; Scherbaum N
Front Psychiatry; 2022; 13():1041762. PubMed ID: 36465301
[TBL] [Abstract][Full Text] [Related]
13. Improved syringe disposal practices associated with unsanctioned safe consumption site use: A cohort study of people who inject drugs in the United States.
Kral AH; Lambdin BH; Wenger LD; Browne EN; Suen LW; Davidson PJ
Drug Alcohol Depend; 2021 Dec; 229(Pt A):109075. PubMed ID: 34654588
[TBL] [Abstract][Full Text] [Related]
14. N
Ordean A; Wong S; Graves L
J Obstet Gynaecol Can; 2017 Oct; 39(10):938-956.e3. PubMed ID: 28935058
[TBL] [Abstract][Full Text] [Related]
15. Directive clinique n
Wilson RD; O'Connor DL
J Obstet Gynaecol Can; 2022 Jun; 44(6):720-732.e1. PubMed ID: 35691684
[TBL] [Abstract][Full Text] [Related]
16. Enough sterile syringes to prevent HIV transmission among injection drug users in Montreal?
Remis RS; Bruneau J; Hankins CA
J Acquir Immune Defic Syndr Hum Retrovirol; 1998; 18 Suppl 1():S57-9. PubMed ID: 9663625
[TBL] [Abstract][Full Text] [Related]
17. TABADO 2 : une stratégie d'accompagnement au sevrage tabagique des adolescents en milieu scolaire.
Vallata A; Cadeville M; Kanski C; Alla F
Glob Health Promot; 2022 Mar; 29(1):130-138. PubMed ID: 33740883
[TBL] [Abstract][Full Text] [Related]
18. Parent-adolescent communication in foster, inter-country adoptive, and biological Italian families: Gender and generational differences.
Rosnati R; Iafrate R; Scabini E
Int J Psychol; 2007 Feb; 42(1):36-45. PubMed ID: 24274778
[TBL] [Abstract][Full Text] [Related]
19. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003.
Emmanuelli J; Desenclos JC
Addiction; 2005 Nov; 100(11):1690-700. PubMed ID: 16277629
[TBL] [Abstract][Full Text] [Related]
20. [Buprenorphine abuse: high dose intravenous administration of buprenorphine].
Varescon I; Vidal-Trécan G; Nabet N; Boissonnas A
Encephale; 2002; 28(5 Pt 1):397-402. PubMed ID: 12386540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
